Afluria Triv 2024-25 (3Yr Up)

Drug overview for AFLURIA TRIV 2024-25 (3YR UP) (influenza virus vaccine trival split 2024-25 (36 mos up)/pf):

Generic name: INFLUENZA VIRUS VACCINE TRIVAL SPLIT 2024-25 (36 MOS UP)/PF (IN-floo-EN-za)
Drug class: Influenza Vaccine
Therapeutic class: Biologicals

No enhanced Introduction information available for this drug.

No enhanced Uses information available for this drug.

DRUG IMAGES

No Image Available

The following indications for AFLURIA TRIV 2024-25 (3YR UP) (influenza virus vaccine trival split 2024-25 (36 mos up)/pf) have been approved by the FDA:

Indications:
Influenza vaccination

Professional Synonyms:
Vaccination to prevent influenza

Dosing information for AFLURIA TRIV 2024-25 (3YR UP)
DRUG LABEL	DOSING TYPE	DOSING INSTRUCTIONS
AFLURIA TRIVA 2024-25 (3YR UP)	Maintenance	Adults inject 0.5 milliliter (45 mcg) by intramuscular route once

Severe List
Guillain-barre syndrome

The following adverse reaction information is available for AFLURIA TRIV 2024-25 (3YR UP) (influenza virus vaccine trival split 2024-25 (36 mos up)/pf):

Overview
Severe
Less Severe

Adverse reaction overview.

No enhanced Common Adverse Effects information available for this drug.

There are 15 severe adverse reactions.

More Frequent	Less Frequent
None.	None.

Rare/Very Rare
Anaphylaxis Angioedema Bell's palsy Brachial plexus disorder Cellulitis Dyspnea Encephalopathy Guillain-barre syndrome Hypersensitivity drug reaction Myelitis Optic neuritis Serum sickness Stevens-johnson syndrome Thrombocytopenic disorder Vasculitis

There are 34 less severe adverse reactions.

More Frequent	Less Frequent
Bruising Chills Erythema Fatigue Headache disorder Induration of skin Injection site pain Injection site sequelae Malaise Myalgia Pruritus of skin	Appetite changes Arthralgia Cough Diarrhea Ecchymosis Fever Injection site erythema Injection site inflammation Nausea Pharyngitis Vomiting

Rare/Very Rare
Back pain Dizziness Extensive limb swelling after injection Flushing Lymphadenopathy Neuralgia Pain in oropharynx Paresthesia Seizure disorder Skin rash Syncope Urticaria

The following precautions are available for AFLURIA TRIV 2024-25 (3YR UP) (influenza virus vaccine trival split 2024-25 (36 mos up)/pf):

Pediatric
Pregnant
Lactation
Geriatric

No enhanced Pediatric Use information available for this drug.

Contraindicated

None

Severe Precaution

None

Management or Monitoring Precaution

None

No enhanced Pregnancy information available for this drug.

No enhanced Lactation information available for this drug.

No enhanced Geriatric Use information available for this drug.

Influenza vaccination
Z23	Encounter for immunization